source
- Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalAn arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for…BioPharma Dive · 23d ago↗ source
- Another big premium hike on the horizonFDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning RoundsSTAT · 23d ago↗ source
- Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnershipsSino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to AstraZ…Endpoints